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Summary
 
Ligation of cytotoxic T lymphocyte antigen 4 (CTLA4) appears to inhibit T cell responses.
Four mechanisms have been proposed to explain the inhibitory activity of CTLA4: competi-
tion for B7-1 and B7-2 binding by CD28; sequestration of signaling molecules away from
CD28 via endocytosis; delivery of a signal that antagonizes a CD28 signal; and delivery of a sig-
nal that antagonizes a T cell receptor (TCR) signal. As three of these potential mechanisms in-
volve functional antagonism of CD28, an experimental model was designed to determine
whether CTLA4 could inhibit T cell function in the absence of CD28. TCR transgenic/re-
combinase activating gene 2–deficient/CD28–wild-type or CD28-deficient mice were gener-
ated and immunized with an antigen-expressing tumor. Primed T cells from both types of mice
produced cytokines and proliferated in response to stimulator cells lacking B7 expression.
However, whereas the response of CD28
 
1
 
/
 
1
 
 T cells was augmented by costimulation with B7-1,
the response of the CD28
 
2
 
/
 
2
 
 T cells was strongly inhibited. This inhibition was reversed by
monoclonal antibody against B7-1 or CTLA4. Thus, CTLA4 can potently inhibit T cell acti-
vation in the absence of CD28, indicating that antagonism of a TCR-mediated signal is suffi-
cient to explain the inhibitory effect of CTLA4.
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D28 is a costimulatory receptor expressed constitu-
tively on naive and on differentiated T cells. Ligation
of CD28 on naive T cells using specific mAb or via its nat-
ural ligands B7-1 or B7-2 augments cytokine production
and proliferation, and promotes differentiation into effector
cells (1). In vitro, CD28 ligation appears to promote T cell
survival via upregulation of Bcl-x
 
L
 
 (2). CD28 costimulation
also prevents induction of anergy in differentiated Th1
clones (3–5), whereas proliferation of differentiated Th2
cells can be relatively CD28 independent (5).
CD28-deficient mice have been generated by homolo-
gous recombination (6). Although B7-dependent activa-
tion of naive CD28
 
2
 
/
 
2
 
 T cells in vitro does not occur (7),
CD28
 
2
 
/
 
2
 
 mice do appear capable of mounting effective
cellular immune responses in vivo, albeit with slower ki-
netics (8). Thus, either some immune responses can occur
in the absence of any costimulatory receptor engagement,
or alternative costimulator molecules exist that can com-
pensate for the absence of CD28 in vivo.
Cytotoxic T lymphocyte antigen 4 (CTLA4) is an alter-
native counterreceptor for B7-1 and B7-2 that is expressed
on T cells only after activation and that binds these ligands
at higher affinity than does CD28 (9, 10). CTLA4 expres-
sion is induced transcriptionally upon TCR–CD3 ligation,
but accumulates predominantly as an intracellular pool in
activated cells. A fraction of CTLA4 molecules is con-
stantly transported to the surface and is subsequently en-
docytosed by a clathrin-mediated mechanism (11, 12). In
contrast to CD28, ligation of CTLA4 appears to inhibit T
cell activation events (13). Perhaps the best evidence that
CTLA4 is a negative regulator of T cell activation has come
from the generation of CTLA4-deficient mice, which ex-
hibit a profound lymphoproliferative syndrome resulting in
death within several weeks of age (14, 15). Other experi-
mental models analyzing CTLA4 function have used stim-
ulation of normal LN T cells with specific mAb against
CD3 and CD28, with or without the addition of anti-
CTLA4 mAb (16, 17). Under these conditions, CTLA4 li-
gation inhibits IL-2 production and proliferation, prevents
sustained IL-2R induction, and induces G1 cell cycle ar-
rest. We have observed recently that differentiated Th1 and
Th2 clones are both susceptible to inhibition by CTLA4
(Alegre, M.L., H. Shiels, C.B. Thompson, and T.F. Gajew-
ski, manuscript submitted for publication). Cross-linking of
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CTLA4 inhibited production of all measurable cytokines
by both T cell subsets, suggesting that the biochemical
mechanism by which CTLA4 antagonizes T cell activation
involves a central signaling pathway vital for multiple TCR-
mediated functions.
At least four mechanisms have been proposed to explain
the inhibitory activity of CTLA4: competition for ligand
access to CD28, thus preventing CD28 from binding to
B7-1 and B7-2; “stealing” of signaling molecules away
from CD28 via the rapid endocytosis of CTLA4; delivery
of a signal that antagonizes or aborts a CD28 signal; and de-
livery of a signal that antagonizes or aborts a TCR-deliv-
ered signal. As the first three of these putative mechanisms
depend on the presence of CD28, an experimental model
was designed to determine whether CTLA4 could inhibit
T cell function in the absence of CD28.
The 2C TCR transgenic (Tg) mouse expresses a TCR
that recognizes the alloantigen L
 
d
 
 bound to a ubiquitous
self peptide from 
 
a
 
-ketoglutarate dehydrogenase (18). These
mice were bred to a recombinase activating gene 2 (Rag2)-
deficient background, to extinguish expression of endog-
enous TCR genes and to ensure a naive T cell phenotype.
2C 
 
3
 
 Rag2-deficient (2C/Rag) mice successfully reject
L
 
d
 
-expressing P815 tumors in a B7-independent fashion
(19). 2C/Rag mice were also crossed with CD28-deficient
mice (generating 2C/Rag/CD28
 
2
 
/
 
2
 
 mice), which were
found to reject P815 tumors in vivo as well. The majority
of T cells from both 2C/Rag/CD28
 
1
 
/
 
1
 
 and 2C/Rag/
CD28
 
2
 
/
 
2
 
 mice appeared to be primed after tumor rejec-
tion, and produced cytokines and proliferated in vitro in
response to P815 stimulator cells lacking B7 expression.
However, whereas the response of primed CD28
 
1
 
/
 
1
 
 T
cells in vitro was augmented by costimulation with B7-1,
the response of primed CD28
 
2
 
/
 
2
 
 T cells was strongly in-
hibited. This inhibition was reversed by mAb against B7-1
or CTLA4. Thus, CTLA4 can potently inhibit the activa-
tion of primed T cells in the absence of CD28, indicating
that antagonism of a TCR-mediated signal is sufficient to
explain its inhibitory effect.
 
Materials and Methods
 
Mice.
 
2C TCR Tg mice were developed as described previ-
ously (18) and obtained from Dr. D. Loh (Washington University
School of Medicine, St. Louis, MO). These were intercrossed
with Rag2-deficient mice (kindly provided by Dr. C. Simon,
University of Chicago) to obtain 2C 
 
3
 
 Rag2
 
2
 
/
 
2
 
 mice (2C/Rag
mice). CD28-deficient mice (obtained from Drs. J. Bluestone and
C. Thompson, University of Chicago) were bred to 2C/Rag
mice to obtain 2C 
 
3
 
 Rag2
 
2
 
/
 
2
 
 
 
3
 
 CD28
 
2
 
/
 
2
 
 mice (2C/Rag/
CD28
 
2
 
/
 
2
 
 mice). All Tg mice were bred in a specific pathogen–
free barrier facility at the University of Chicago. Mice were used
at 6–8 wk of age for experiments.
 
Cell Lines and Transfectants.
 
P815 mastocytoma cells were
cultured in DMEM supplemented with 10% FCS and incubated
at 37
 
8
 
C in an 8% CO
 
2
 
 atmosphere. P815.B7-1 was derived and
maintained as described (Fields, P.E., S. Wolf, T.F. Gajewski, and
F.W. Fitch, manuscript submitted for publication). P1.HTR is a
highly transfectable variant of P815 that grows semiadherent in
tissue culture and as a solid tumor mass when implanted subcuta-
neously in vivo (20), and was used for in vivo tumor rejection.
 
In Vivo Priming of 2C/Rag/CD28–wild-type or CD28-deficient
Mice.
 
2C/Rag or 2C/Rag/CD28
 
2
 
/
 
2
 
 mice were immunized
subcutaneously in the left flank with 10 
 
3
 
 10
 
6
 
 living P1.HTR tu-
mor cells in 100 
 
m
 
l Dulbecco’s PBS. The animals were killed 10 d
after immunization, and splenic CD8
 
1
 
 T cells were purified. Af-
ter confirmation of purity by flow cytometry, cells were stimu-
lated to assess proliferation and cytokine production.
 
Purification of CD8
 
1
 
 T Cells.
 
CD8
 
1
 
 cells were isolated by
negative enrichment using a magnetic separation system (Stem-
Cell Technologies, Vancouver, B.C., Canada) according to the
manufacturer’s protocol. The purity of the eluted fraction, deter-
mined by flow cytometry using the clonotypic Ab 1B2 or anti-
CD8 mAb, ranged between 92 and 96%.
 
Antibodies and Flow Cytometry.
 
For flow cytometry, PE-cou-
pled anti-CTLA4 mAb 4F10 (PharMingen, San Diego, CA),
FITC-coupled 1B2 (prepared in our laboratory), and biotinylated
anti-CD28 mAb (PharMingen) were used. Expression of the
TCR and of CD28 was determined by normal surface staining,
whereas CTLA4 expression was assessed after saponin permeabili-
zation, as described (12). In both cases, nonspecific staining was
reduced by blocking with the anti-FcR
 
g
 
 mAb 2.4G2. Samples
were analyzed on a FACScan
 
Ò
 
 (Becton Dickinson, San Jose, CA),
and data were analyzed using Lysis II software (Becton Dickinson).
Live cells were selected for analysis using forward versus side scatter
gating. Nonconjugated mAb against B7-1 (16-10A1) or CTLA4
(4F10) were used for in vitro blocking experiments.
 
T Cell Proliferation Assay.
 
CD8
 
1
 
 T cells (3 
 
3
 
 10
 
4
 
) were mixed
with 3 
 
3
 
 10
 
4
 
 mitomycin C–treated P815 or P815.B7-1 tumor
cells along with the indicated concentrations of various reagents
in microtiter plates in a final volume of 200 
 
m
 
l. Cultures were
pulsed at various times with 1 
 
m
 
Ci of [
 
3
 
H]thymidine and har-
vested 8 h later onto glass filters using a 96-well plate harvester
(Packard, Meriden, CT). Incorporated radioactivity was assessed
using a Top Count microplate scintillation counter (Packard).
 
Stimulation of T Cells for Lymphokine Production and CTLA4 Ex-
pression.
 
For lymphokine production, purified CD8
 
1
 
 T cells
(2.5 
 
3
 
 10
 
5
 
) were stimulated with mitomycin C–treated P815 or
P815-B7.1 tumor cells (2.5 
 
3
 
 10
 
5
 
) in a total volume of 1 ml. In
some experiments, stimulation was performed in the presence of
anti-CTLA4 mAb (50 
 
m
 
g/ml final), anti–B7-1 mAb (1 
 
m
 
g/ml fi-
nal), or the combination. Supernatants were collected at 24 h to
determine IL-2 production and at 48 h to assess IFN-
 
g
 
 content.
To stimulate for measurement of CTLA4 expression, purified
CD8
 
1
 
 T cells (5 
 
3
 
 10
 
5
 
) were restimulated in vitro in the presence
of mitomycin C–treated P815-B7.1 (2.5 
 
3
 
 10
 
5
 
) tumor cells for
48–72 h in a total volume of 1.5 ml. Flow cytometric analysis was
then performed on permeabilized cells using anti-CTLA4 mAb.
 
Lymphokine Assays.
 
IFN-
 
g
 
 concentrations were determined
using an ELISA developed by Dr. R. Schreiber (Washington
University), who also provided the reagents. IL-2 was measured
using an ELISA with antibody pairs obtained from PharMingen.
Concentrations were expressed in U/ml as determined using the
respective recombinant cytokines as standards.
 
Results
 
Characterization of 2C/Rag/CD28–wild-type and CD28-
deficient Mice. 
 
2C TCR Tg mice were bred to a Rag2-
deficient background to extinguish expression of endoge-
nous TCR genes and ensure a naive phenotype (reference 
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19, and data not shown). We have observed previously that
2C/Rag mice vigorously reject L
 
d
 
-expressing P815 tumors,
resulting in priming of the majority of the T cells in the
mouse based on surface expression of CD44 and CD62L as
well as induction of cytolytic activity (19). Thus, tumor
rejection provides a convenient means by which to immu-
nize these mice. Priming occurred even in mice treated
with CTLA4-Ig, arguing that it can be achieved in the ab-
sence of B7–CD28 interactions. Indeed, 2C/Rag/CD28
 
2
 
/
 
2
 
mice also were found to reject P815 tumors in vivo, result-
ing in comparable induction of activation markers and cy-
tolytic activity as is seen with the 2C/Rag/CD28
 
1
 
/
 
1
 
 mice
(data not shown). Use of primed T cells from these immu-
nized mice provided a means by which to examine a po-
tential inhibitory role of CTLA4 in the absence of CD28.
To determine whether expression of CTLA4 could indeed
be induced in 2C/Rag/CD28
 
2
 
/
 
2
 
 T cells, flow cytometric
analysis was performed after restimulation in vitro with P815
cells. As shown in Fig. 1, surface expression of the TCR, as
detected by the clonotypic mAb 1B2, was comparable on
the CD28
 
1
 
/
 
1
 
 and CD28
 
2
 
/
 
2
 
 T cells, whereas CD28 was ex-
pressed only on the CD28
 
1
 
/
 
1
 
 T cells, as expected. Interest-
ingly, total cellular CTLA4 expression analyzed on perme-
abilized cells was comparable in T cells from both mice (Fig.
1), indicating that CTLA4 indeed has an opportunity to an-
tagonize T cell function even in CD28-deficient T cells.
 
Response of 2C/Rag/CD28
 
1
 
/
 
1
 
 or 2C/Rag/CD28
 
2
 
/
 
2
 
 T
Cells to B7-1 Costimulation In Vitro. 
 
We have observed re-
cently  that in contrast to naive T cells which are dependent
on CD28 costimulation for primary activation in vitro, sec-
ondary (primed) T cells proliferate and produce IL-2 after
TCR stimulation alone (Fields, P.E., S. Wolf, T.F. Gajew-
ski, and F.W. Fitch, manuscript submitted for publication).
To determine the effect of B7-1 on the response of primed
T cells that express or do not express CD28, in vivo–primed
2C/Rag/CD28–wild-type or CD28-deficient T cells were
stimulated with P815 or P815.B7-1 cells, and proliferation
was measured over time. As shown in Fig. 2 
 
A
 
, primed
CD28
 
1
 
/
 
1
 
 T cells proliferated in response to P815, with a
peak response observed on day 2. This proliferation was aug-
mented and extended if B7-1 was expressed on the P815
stimulator cells. The CD28
 
2
 
/
 
2
 
 cells also proliferated in re-
sponse to nontransfected P815 cells (Fig. 2 
 
B
 
). However, in
this case, expression of B7-1 on the stimulator cells resulted
in nearly complete inhibition of the proliferative response.
When cytokine production was examined, the effect of
B7-1 on the response of CD28
 
1
 
/
 
1
 
 and CD28
 
2
 
/
 
2
 
 T cells
was similar to the effect seen on the proliferation of these
cells. As shown in Fig. 3, P815.B7-1 cells generally stimu-
lated equivalent or increased levels of IL-2 (
 
A
 
) and IFN-
 
g
 
(
 
B
 
) production compared with nontransfected P815 cells
when primed 2C/Rag/CD28
 
1
 
/
 
1
 
 T cells were examined.
The magnitude of augmentation of detectable IL-2 pro-
duction by B7-1 was variable between experiments, pre-
sumably due to variable rates of IL-2 consumption by the
proliferating T cells. In contrast, when 2C/Rag/CD28
 
2
 
/
 
2
T cells were examined, P815.B7-1 cells induced pro-
foundly reduced levels of IL-2 and IFN-g release compared
Figure 1. Flow cytometric analysis of T cells from mu-
tant mice. 2C/Rag/CD281/1 and CD282/2 mice were
immunized by in vivo rejection of P1.HTR tumor cells.
Splenic T cells were purified and restimulated for 2 d with
mitomycin C–treated P815 cells to assess expression of
TCR, CD28, and CTLA4. Flow cytometric analysis was
performed after surface staining using the clonotypic TCR
antibody 1B2 or the anti-CD28 mAb 37.51, or after intra-
cellular staining with the anti-CTLA4 mAb 4F10. Similar
results were obtained in three separate experiments.
Figure 2. Time course of proliferation of
CD281/1 or CD282/2 TCR Tg T cells in response
to B7-11 or B7-12 stimulator cells. CD81 T cells
purified by negative selection from primed CD281/1
or CD282/2 2C/Rag22/2 mice were stimulated
with mitomycin C–treated P815 or P815.B71 cells.
Replicate cultures were pulsed daily with [3H]thy-
midine and harvested, and incorporated radioactiv-
ity was assessed. Similar results were obtained in at
least two experiments.208 CD28-independent Inhibition of T Cells by CTLA4
with those induced by nontransfected P815 stimulators
(Fig. 3). These reduced levels were usually near the back-
ground levels of detection for the respective assays. Thus,
the effect of B7-1 on primed CD28-deficient T cells is in-
hibitory rather than stimulatory for cytokine production
and proliferation.
Inhibition of Activation of 2C/Rag/CD282/2 T Cells by
P815.B7-1 Cells Is Reversed by Anti–B7-1 or Anti-CTLA4
mAb. To confirm that the decreased ability of P815.B7-1
to stimulate 2C/Rag/CD282/2 T cells was directly medi-
ated by B7-1 and CTLA4, neutralizing mAbs against these
respective molecules were included during T cell stimula-
tion. As shown in Fig. 4, the augmented IL-2 production
by CD281/1 cells promoted by B7-1 costimulation was
blocked by anti–B7-1 mAb. In contrast, the decreased IL-2
production by CD282/2 T cells in the presence of B7-1
costimulation was reversed with the addition of anti–B7-1
mAb. Likewise, whereas anti-CTLA4 mAb had a slight
augmentative effect on IL-2 production by the CD281/1 T
cells, the decreased IL-2 production of CD282/2 T cells in
the presence of P815.B7-1 was reversed completely in the
presence of anti-CTLA4 mAb (Fig. 4). The combination
of both mAbs gave similar results to those seen with anti–
B7-1 mAb alone. Thus, B7-1 expression on stimulator cells
apparently can inhibit the activation of CD28-deficient T
cells via ligation of CTLA4.
Discussion
Most experimental evidence obtained to date is consis-
tent with a negative regulatory function of CTLA4 on T
cells. Blockade of CTLA4 interactions using neutralizing
mAb augments T cell proliferation in vitro (21), promotes
tumor rejection in vivo (22), and appears to prevent anti-
gen-specific tolerance in vivo (23, 24). Conversely, cross-
linking of CTLA4 inhibits IL-2 production and prolifera-
tion of normal LN T cells in vitro (16, 25). In each of these
settings, T cell responses were first optimized by ensuring
CD28 ligation, either with anti-CD28 mAb or via pre-
sumed interaction with natural ligands, and CTLA4 was
manipulated within that context. Therefore, these experi-
mental systems have led to the proposal that CTLA4 may
antagonize a CD28-mediated signal. Such a model appears
intuitive as well; B7 ligands could first engage the positive
receptor CD28, and then subsequent induction of CTLA4
could force the same B7 ligands to mediate a negative re-
sponse through CTLA4, reversing the CD28 effect.
In this study, we took advantage of the observation that
primed T cells exhibit a relaxed requirement for CD28 co-
stimulation, such that substantial cytokine production and
proliferation can be observed in response to TCR ligation
alone. In this way, the potential for CTLA4 to inhibit T
cell function in the absence of CD28 could be examined.
In addition, by using primed CD28-deficient T cells,
CTLA4 could be stimulated with the natural ligand B7-1
rather than using cross-linked anti-CTLA4 mAb. Indeed,
B7-1 clearly inhibited rather than augmented T cell activa-
tion in the absence of CD28, in a CTLA4-dependent fash-
ion. These data support previous observations that CTLA4
is a negative regulator of T cell activation. However, these
results also indicate that CTLA4 can exert its inhibitory ef-
fect in the absence of CD28.
It is likely that CTLA4 antagonizes a signal delivered
through the TCR–CD3 complex. However, our studies
do not exclude the possibility that CTLA4 signaling can in-
hibit the function of an undefined alternative costimulatory
receptor, or that CTLA4 can additionally inhibit a CD28
Figure 3. Cytokine production by CD281/1 or
CD282/2 TCR Tg T cells in response to B7-11 or
B7-12 stimulator cells. CD81 T cells purified as in
Fig. 2 were stimulated with mitomycin C–treated
P815 or P815.B71 cells. Supernatants were col-
lected, and IL-2 and IFN-g content were assessed.
Similar results were obtained in at least three ex-
periments.
Figure 4. Inhibition of cytokine production of CD282/2 T cells by
B7-1 transfectants is prevented by anti–B7-1 or by anti-CTLA4 mAb. T
cell stimulations were performed as in Fig. 3 without additions, or in the
presence of anti–B7-1 mAb, anti-CTLA4 mAb, or the combination. IL-2
production was determined at 24 h. Similar results were obtained for
IFN-g production (data not shown), and in at least two separate experi-
ments.209 Fallarino et al. Brief Definitive Report
signal. Given the conclusions of this study, we have exam-
ined recently whether cross-linking of CTLA4 can abort
ongoing signaling events initiated through CD3 cross-link-
ing alone. Preliminary results have revealed that the normal
prolonged activation of extracellular signal–regulated kinase
(ERK)1 and ERK2 in response to CD3 ligation becomes
inactivated once CTLA4 expression emerges and is itself
cross-linked (data not shown). These results are consistent
with a recent published report indicating that, using 3-d–stim-
ulated T cells that have maximal surface expression of CTLA4,
restimulation in the presence of CTLA4 cross-linking re-
sults in reduced activation of ERK and jun NH2-terminal
kinase (26). Thus, blockade of a TCR–CD3-mediated sig-
nal is sufficient to explain the inhibitory effect of CTLA4.
The biochemical mechanism by which CTLA4 antago-
nizes T cell responses is not yet understood. Like CD28,
the cytoplasmic tail of CTLA4 contains a binding motif for
phosphatidylinositol (PI)3-kinase, and interaction between
phosphorylated CTLA4 and PI3-kinase has been demon-
strated (27, 28). CTLA4 can be phosphorylated in the pres-
ence of activated Lck in vivo (29). However, since CD28
also binds PI3-kinase, it is unclear how this interaction
would mediate a negative signal for CTLA4. The protein
tyrosine phosphatase PTP1D has been reported to interact
with CTLA4 (30), although this interaction may be non-
specific (data not shown). Nonetheless, it is attractive to
speculate that CTLA4 may bring a phosphatase into the
TCR–CD3 complex through cocapping, thus dephosphor-
ylating a key substrate that is necessary to sustain T cell sig-
naling. We have observed recently, using differentiated
Th1 and Th2 clones, that production of all cytokines was
modulated by CTLA4 manipulation. Since activation of
ERK1/ERK2 is easily demonstrated in both T cell subsets,
and since this pathway may be required for cytokine gene
expression, a substrate downstream from the TCR but
proximal to ERK1/ERK2 may be one target of CTLA4
inhibition. This target is likely to be downstream from
CD3z phosphorylation and ZAP70 recruitment, since
these events have been reported to be unaffected by
CTLA4 ligation (26).
In summary, our results support a model in which
CTLA4 ligation antagonizes a TCR-driven signal rather
than a CD28-dependent signaling event. Thus, rather than
CD28 costimulation augmenting a TCR signal and CTLA4
inhibiting this CD28 costimulus, CD28 and CTLA4 may
instead antagonistically regulate the same TCR-mediated
events. A better understanding of how CTLA4 functions
should aid in the development of agents that either inhibit
or augment ongoing immune responses.
The authors thank J. Bluestone and C. Thompson for providing the CD28-deficient mice, C. Simon for
providing the Rag2-deficient mice, and J. O’Keefe and A. Ashikari for their assistance in mouse screening. 
T. Gajewski is a recipient of a McDonnell Foundation Scholar Award in molecular oncology. This work
was also supported by grant P01 AI35294-05 from the National Institutes of Health, and by a grant from
Pfizer Corporation.
Address correspondence to Thomas F. Gajewski, University of Chicago, 5841 S. Maryland Ave., MC2115,
Chicago, IL 60637. Phone: 773-702-4601; Fax: 773-702-3163; E-mail: tfgajews@mcis.bsd.uchicago.edu
Received 25 March 1998 and in revised form 14 April 1998.
References
1. Lenschow, D.J., T.L. Walunas, and J.A. Bluestone. 1996.
CD28/B7 system of T cell costimulation. Annu. Rev. Immu-
nol. 14:233–258.
2. Boise, L.H., A.J. Minn, P.J. Noel, C.H. June, M.A. Accav-
itti, T. Lindsten, and C.B. Thompson. 1995. CD28 stimula-
tion can enhance T cell survival by inducing expression of
Bcl-xL. Immunity. 3:87–98.
3. Harding, F.A., J.G. McArthur, J.A. Gross, D.H. Raulet, and
J.P. Allison. 1992. CD28-mediated signalling co-stimulates
murine T cells and prevents induction of anergy in T-cell
clones. Nature. 356:607–609.
4. Tan, P., C. Anasetti, J.A. Hansen, J. Melrose, M. Brunvand,
J. Bradshaw, J.A. Ledbetter, and P.S. Linsley. 1993. Induc-
tion of alloantigen-specific hyporesponsiveness in human T
lymphocytes by blocking interaction of CD28 with its natural
ligand B7/BB1. J. Exp. Med. 177:165–173.
5. Gajewski, T.F., D.W. Lancki, R. Stack, and F.W. Fitch.
1994. “Anergy” of TH0 helper T lymphocytes induces
downregulation of TH1 characteristics and a transition to a
TH2-like phenotype. J. Exp. Med. 179:481–491.
6. Shahinian, A., K. Pfeffer, K.P. Lee, T.M. Kundig, K. Kishi-
hara, A. Wakeham, K. Kawai, P.S. Ohashi, C.B. Thompson,
and T.W. Mak. 1993. Differential T cell costimulatory re-
quirements in CD28-deficient mice. Science. 261:609–612.
7. Green, J.M., P.J. Noel, A.I. Sperling, T.L. Walunas, G.S.
Gray, J.A. Bluestone, and C.B. Thompson. 1994. Absence of
B7-dependent responses in CD28-deficient mice. Immunity.
1:501–508.
8. Kawai, K., A. Shahinian, T.W. Mak, and P.S. Ohashi. 1996.
Skin allograft rejection in CD28-deficient mice. Transplanta-
tion (Baltimore). 61:352–355.
9. Linsley, P.S., W. Brady, M. Urnes, L. Grosmaire, N.K.
Damle, and J.A. Ledbetter. 1991. CTLA-4 is a second recep-
tor for the B cell activation antigen B7. J. Exp. Med. 174:
561–569.
10. Linsley, P.S., J.L. Greene, W. Brady, J. Bajorath, J.A. Ledbet-
ter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2
(CD86) bind with similar avidities but distinct kinetics to210 CD28-independent Inhibition of T Cells by CTLA4
CD28 and CTLA-4 receptors. Immunity. 1:793–801.
11. Chuang, E., M.L. Alegre, C.S. Duckett, P.J. Noel, M.G.
Vander Heiden, and C.B. Thompson. 1997. Interaction of
CTLA-4 with the clathrin-associated protein AP50 results in
ligand-independent endocytosis that limits surface expression.
J. Immunol. 159:144–151.
12. Alegre, M.L., P.J. Noel, B.J. Eisfelder, E. Chuang, M.R.
Clark, S.L. Reiner, and C.B. Thompson. 1996. Regulation
of surface expression and intracellular expression of CTLA4
on mouse T cells. J. Immunol. 157:4762–4770.
13. Thompson, C.B., and J.P. Allison. 1997. The emerging role
of CTLA-4 as an immune attenuator. Immunity. 7:445–450.
14. Tivol, E.A., F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A.
Bluestone, and A.H. Sharpe. 1995. Loss of CTLA4 leads to
massive lymphoproliferation and fatal multiorgan tissue de-
struction, revealing a critical negative regulatory role of
CTLA4.  Immunity. 3:541–547.
15. Waterhouse, P., J.M. Penninger, E. Timms, A. Wakeham, A.
Shahinian, K.P. Lee, C.B. Thompson, H. Griesser, and T.W.
Mak. 1995. Lymphoproliferative disorders with early lethality
in mice deficient in CTLA-4. Science. 270:985–988.
16. Walunas, T.L., C.Y. Bakker, and J.A. Bluestone. 1996.
CTLA-4 ligation blocks CD28-dependent T cell activation.
J. Exp. Med. 183:2541–2550.
17. Krummel, M.F., and J.P. Allison. 1996. CTLA-4 engage-
ment inhibits IL-2 accumulation and cell cycle progression
upon activation of resting T cells. J. Exp. Med. 183:2533–
2540.
18. Sha, W.C., C.A. Nelson, R.D. Newberry, D.M. Kranz, J.H.
Russell, and D.Y. Loh. 1988. Selective expression of an anti-
gen receptor on CD8-bearing T lymphocytes in transgenic
mice. Nature. 335:271–275.
19. Manning, T.C., L.A. Rund, M.M. Gruber, F. Fallarino, T.F.
Gajewski, and D.M. Kranz. 1997. Antigen recognition and
allogeneic tumor rejection in CD81 TCR transgenic/Rag2/2
mice. J. Immunol. 159:4665–4675.
20. Gajewski, T.F., C. Uyttenhove, F. Fallarino, and T. Boon.
1996. Tumor rejection requires a CTLA4 ligand provided by
the host or expressed on the tumor: superiority of B7-1 over
B7-2 for active tumor immunization. J. Immunol. 156:2909–
2917.
21. Walunas, T.L., D.J. Lenschow, C.Y. Bakker, P.S. Linsley,
G.J. Freeman, J.M. Green, C.B. Thompson, and J.A. Blue-
stone. 1994. CTLA-4 can function as a negative regulator of
T cell activation. Immunity. 1:405–413.
22. Leach, D.R., M.F. Krummel, and J.P. Allison. 1996. En-
hancement of antitumor immunity by CTLA-4 blockade.
Science. 271:1734–1736.
23. Perez, V.L., L. Van Parijs, A. Biuckians, X.X. Zheng, T.B.
Strom, and A.K. Abbas. 1997. Induction of peripheral T cell
tolerance in vivo requires CTLA-4 engagement. Immunity. 6:
411–417.
24. Bluestone, J.A. 1997. Is CTLA-4 a master switch for periph-
eral T cell tolerance? J. Immunol. 158:1989–1993.
25. Krummel, M.F., and J.P. Allison. 1995. CD28 and CTLA-4
have opposing effects on the response of T cells to stimula-
tion. J. Exp. Med. 182:459–465.
26. Calvo, C.R., D. Amsen, and A.M. Kruisbeek. 1997. Cyto-
toxic T lymphocyte antigen 4 (CTLA-4) interferes with ex-
tracellular signal-regulated kinase (ERK) and jun NH2-termi-
nal kinase (JNK) activation, but does not affect phosphorylation
of T cell receptor z and ZAP70. J. Exp. Med. 186:1645–
1653.
27. Schneider, H., K.V.S. Prasad, S.E. Shoelson, and C.E. Rudd.
1995. CTLA-4 binding to the lipid kinase phosphatidylinosi-
tol 3-kinase in T cells. J. Exp. Med. 181:351–355.
28. Hutchcroft, J.E., and B.E. Bierer. 1996. Signaling through
CD28/CTLA-4 family receptors. Puzzling participation of
phosphatidylinositol-3 kinase. J. Immunol. 157:4071–4074.
29. Rudd, C.E., H. Hu, M. Raab, D. Cefai, and H. Schneider.
1997. CD28 and CTLA-4 regulation of interleukin 2 pro-
duction in T cells. J. Allergy Clin. Immunol. 99:S206. (Abstr.)
30. Marengere, L.E.M., P. Waterhouse, G.S. Duncan, H.W.
Mittrucker, G.S. Feng, and T.W. Mak. 1996. Regulation of
T cell receptor signaling by tyrosine phosphatase SYP associ-
ation with CTLA-4. Science. 272:1170–1173.